急性心力衰竭中方案化利尿钠指导的利尿剂治疗:系统评价与荟萃分析
该系统评价与荟萃分析纳入3项随机对照试验和2项观察性研究,共933例急性心力衰竭患者,其中404例(43%)接受利尿钠指导治疗。方案化治疗在48小时后显著增加利尿钠(几何均数比1.30,95%CI 1.14至1.49)和利尿(几何均数比1.21,95%CI 1.09至1.35)。体重减轻、住院时长、心衰再住院或全因死亡无显著差异。方案化治疗与血清肌酐翻倍风险降低相关(RR 0.52,95%CI 0.28至0.98),且不增加低钾血症或低血压风险。
要点
- 在急性心衰患者中,方案化利尿钠指导治疗48小时后利尿钠增加(GMR 1.30,95%CI 1.14至1.49),利尿增加(GMR 1.21,95%CI 1.09至1.35)。
- 方案化治疗与血清肌酐翻倍风险降低相关(RR 0.52,95%CI 0.28至0.98),且不增加低钾血症或低血压风险。
- 体重减轻、住院时长、心衰再住院和全因死亡在方案化治疗与标准管理之间无显著差异。
- 仅限随机对照试验的敏感性分析确认了所有疗效和安全性终点的发现。
适用人群与场景
- 急性心力衰竭患者,来自3项随机对照试验和2项观察性研究,共933例,其中404例(43%)在利尿钠指导治疗组。
研究设计与关键结果
- 研究类型为系统评价与荟萃分析,纳入3项随机对照试验和2项观察性研究,共933例急性心衰患者,其中404例(43%)接受利尿钠指导治疗。
- 主要终点:48小时后利尿钠几何均数比1.30(95%CI 1.14至1.49),利尿几何均数比1.21(95%CI 1.09至1.35),方案化治疗均显著增加。
- 关键次要终点:体重减轻、住院时长、心衰再住院、全因死亡均无显著差异;血清肌酐翻倍风险RR 0.52(95%CI 0.28至0.98),方案化治疗组更低。
- 不良事件:不增加低钾血症或低血压风险。
- 敏感性分析仅限随机对照试验,确认所有疗效和安全性终点的发现。
证据类型、等级与局限
- 证据类型为系统评价与荟萃分析,纳入3项随机对照试验和2项观察性研究。
- 偏倚风险:2项随机对照试验经RoB 2工具评为「低」风险,Bayat等研究评为「有些担忧」;ENACT-HF研究经ROBINS-I工具评为「中度」风险,Pellegrino等研究评为「严重」风险。
- 局限:需要进一步大规模随机对照试验来评估对不同医疗环境和全球患者临床终点的影响。
对床旁实践的改变
- 在急性心衰患者中,方案化利尿钠指导的利尿剂治疗可增加48小时利尿钠和利尿,并降低血清肌酐翻倍风险,且不增加低钾血症或低血压风险。
- 作者认为短期安全性和有效性有前景,但需要进一步大规模随机对照试验评估对不同医疗环境和全球患者临床终点的影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Volume overload is the primary pathophysiological mechanism underlying signs and symptoms in acute heart failure (AHF). However, evidence-based strategies for optimal loop diuretic dosing and monitoring remain limited. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of natriuresis-guided protocols for titrating diuretic therapy in patients with AHF.
METHODS: We searched Cochrane, PubMed, and Embase databases for studies that compared natriuresis-guided diuretic therapy versus standard management in patients with AHF from their inception until June 2025. We computed pooled risk ratio (RR) for binary outcomes, and for continuous outcomes, we calculated either pooled mean difference (MD) or geometric mean ratio (GMR) derived from differences in log-means, all with 95% confidence intervals (CIs). Data from the studies were pooled using R version 4.4.1. Risk of bias was assessed using RoB 2 and ROBINS-I tools. We also performed a sensitivity analysis restricted to randomized controlled trials (RCTs).
RESULTS: Three RCTs and two observational studies were included, encompassing 933 patients, of which 404 (43%) were in the natriuresis-guided therapy group. Protocolized therapy significantly increased natriuresis (GMR: 1.30; 95% CI: 1.14 to 1.49) and diuresis (GMR: 1.21; 95% CI: 1.09 to 1.35) after 48 h. No significant differences were observed in weight loss, length of hospital stay, heart failure rehospitalization, or all-cause mortality. Protocolized therapy was associated with a lower risk of doubling serum creatinine (RR: 0.52; 95% CI: 0.28 to 0.98), without increasing the risk of hypokalemia or hypotension. Two RCTs were deemed at "low" risk of bias by the RoB 2 tool, while Bayat et al. was rated as having "some concerns." For studies assessed using the ROBINS-I tool, the ENACT-HF study presented a "moderate" risk of bias, and Pellegrino et al. a "serious" risk. Nevertheless, our sensitivity analysis, limited to RCTs, confirmed our findings for all efficacy and safety endpoints.
CONCLUSION: In this meta-analysis of patients with AHF, protocolized natriuresis-guided therapy was safe and associated with improved diuresis and natriuresis after 48 h, as well as a reduced risk of acute kidney injury. While the short-term safety and efficacy are promising, further large RCTs are needed to evaluate the effects on clinical endpoints in diverse healthcare settings and patients worldwide.
参考来源
- Prata AA, Prata AA, Coan ACC, et al. Protocolized natriuresis-guided diuretic therapy in acute heart failure: a systematic review and meta-analysis. Crit Care. 2025. PMID: 41194267. doi:10.1186/s13054-025-05707-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。